top of page
  • Recruiting

NCT04094961: Phase 1/2: Ixazomib + Pomalidomide + Dexamethasone In MM

Updated: Oct 4, 2022

NCT04094961: Phase 1/2: Ixazomib + Pomalidomide + Dexamethasone In MM

ixa-pom-dex

Ixazomib + Pomalidomide + Dexamethasone In MM

This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.


Sponsor

Paul G. Richardson, MD


Collaborator


Information provided by (Responsible Party)

Paul G. Richardson, MD, Dana-Farber Cancer Institute

 

ClinicalTrials.gov Identifier: NCT04094961

Official Title: Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed/or Refractory Multiple Myeloma

First Posted: September 19, 2019

Click here to see details on ClinicalTrials.gov

 

Drug: Ixazomib

Drug: Pomalidomide

Drug: Dexamethasone

 
 

Location

United States, Massachusetts



コメント


Posts Archive
bottom of page